Inhibikase Therapeutics, Inc(NASDAQ:IKT) 
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of P...
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.92
H 1.93
L 1.76
C 1.84
V 139,629
10EMA 1.84
20EMA 1.84
60EMA 1.84
120EMA 1.84
250EMA 1.84